BioStem Technologies Reports Third Quarter 2026 Financial Results; Grows Hospital Revenue for Second Consecutive Quarter as Customers Expand Use of Portfolio
Globe Newswire•12/11/2026•16:05 ET
1
Key Highlights
- ➤Hospital revenue rose sequentially to $6.8 million
- ➤Full-year 2026 revenue guidance raised to $28 million-$29 million
- ➤Third-quarter net revenue declined to $7.6 million from $10.5 million year over year
- ➤GAAP net loss widened to $11.4 million, or $0.64 per share
- ➤Cash fell to $1.0 million; operating cash usage reached $8.8 million
- ➤Neox and Clarix in-house production remains on track for first half of 2027
Expert Statements
Jason Matuszewski, Chair and CEO of BioStem Technologies
“We grew hospital revenue again this quarter, and importantly, are doing so by adding new accounts and increasing penetration with existing customers. The number of customers buying two or more of our product lines grew 14% from the second quarter. We also completed the final step of our commercial infrastructure build-out, and with in-house production of Neox and Clarix expected to begin in the first half of 2027, we are on track to become a fully vertically integrated company with those product lines”
Jason Matuszewski, Chair and CEO of BioStem Technologies
“With these foundations in place, we are focused on strengthening the balance sheet, raising our gross margin, reducing operating expenses and narrowing our adjusted EBITDA loss as we work toward breakeven.”
Hospital revenue grew sequentially to $6.8 million; customers purchasing two or more product lines up 14% from the second quarter
In-house production of Neox(®) and Clarix(®) on track to begin in the first half of 2027
Get started
Create a free account to read the full story.